APA (7th ed.) Citation

Ludvik, B., Giorgino, F., Jódar, E., Frias, J. P., Fernández Landó, L., Brown, K., . . . Rodríguez, Á. (2021). Once-weekly tirzepatide versus once-daily insulin degludec as add-on to metformin with or without SGLT2 inhibitors in patients with type 2 diabetes (SURPASS-3): A randomised, open-label, parallel-group, phase 3 trial. The Lancet (British edition), 398(10300), 583-598. https://doi.org/10.1016/S0140-6736(21)01443-4

Chicago Style (17th ed.) Citation

Ludvik, Bernhard, Francesco Giorgino, Esteban Jódar, Juan P. Frias, Laura Fernández Landó, Katelyn Brown, Ross Bray, and Ángel Rodríguez. "Once-weekly Tirzepatide Versus Once-daily Insulin Degludec as Add-on to Metformin with or Without SGLT2 Inhibitors in Patients with Type 2 Diabetes (SURPASS-3): A Randomised, Open-label, Parallel-group, Phase 3 Trial." The Lancet (British Edition) 398, no. 10300 (2021): 583-598. https://doi.org/10.1016/S0140-6736(21)01443-4.

MLA (9th ed.) Citation

Ludvik, Bernhard, et al. "Once-weekly Tirzepatide Versus Once-daily Insulin Degludec as Add-on to Metformin with or Without SGLT2 Inhibitors in Patients with Type 2 Diabetes (SURPASS-3): A Randomised, Open-label, Parallel-group, Phase 3 Trial." The Lancet (British Edition), vol. 398, no. 10300, 2021, pp. 583-598, https://doi.org/10.1016/S0140-6736(21)01443-4.